Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monopar Therapeutics (MNPR) Assets Average (2018 - 2020)

Historic Assets Average for Monopar Therapeutics (MNPR) over the last 3 years, with Q3 2020 value amounting to $15.5 million.

  • Monopar Therapeutics' Assets Average rose 18923.37% to $15.5 million in Q3 2020 from the same period last year, while for Sep 2020 it was $15.5 million, marking a year-over-year increase of 18923.37%. This contributed to the annual value of $10.3 million for FY2019, which is 1983.14% up from last year.
  • As of Q3 2020, Monopar Therapeutics' Assets Average stood at $15.5 million, which was up 18923.37% from $12.8 million recorded in Q2 2020.
  • In the past 5 years, Monopar Therapeutics' Assets Average registered a high of $15.5 million during Q3 2020, and its lowest value of $5.4 million during Q3 2019.
  • For the 3-year period, Monopar Therapeutics' Assets Average averaged around $9.4 million, with its median value being $8.8 million (2018).
  • As far as peak fluctuations go, Monopar Therapeutics' Assets Average plummeted by 3447.16% in 2019, and later surged by 18923.37% in 2020.
  • Monopar Therapeutics' Assets Average (Quarter) stood at $7.6 million in 2018, then increased by 21.41% to $9.2 million in 2019, then soared by 67.7% to $15.5 million in 2020.
  • Its Assets Average was $15.5 million in Q3 2020, compared to $12.8 million in Q2 2020 and $13.1 million in Q1 2020.